Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
152
Views
10
CrossRef citations to date
0
Altmetric
Review

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic

Ayushi F Chauhan1 Department of Hematology and Oncology, Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington DC, USACorrespondence[email protected]
&
Bruce D Cheson2 Scientific Advisory Board, Lymphoma Research Foundation, Washington, DC, USAORCID Iconhttps://orcid.org/0000-0002-6246-4308
ORCID Icon
Pages 677-692 | Published online: 25 Jan 2021

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Georgios Pongas & Bruce Cheson. (2021) Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 11, pages 55-66.
Read now

Articles from other publishers (9)

Dhanushya Gopal, Rajesh Muthuraj, Rex Devasahayam Arokia Balaya, Saptami Kanekar, Iqrar Ahmed & Jaikanth Chandrasekaran. (2024) Computational discovery of novel FYN kinase inhibitors: a cheminformatics and machine learning-driven approach to targeted cancer and neurodegenerative therapy. Molecular Diversity.
Crossref
Francesc Bosch, John Kuruvilla, Theodoros P. Vassilakopoulos, Danilo Di Maio, Michael C. Wei, Marie-Helene Blanchet Zumofen & Loretta J. Nastoupil. (2024) Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 24:2, pages 105-121.
Crossref
Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, Essa Mohammed Algathlan & Syam Mohan. (2024) Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice. Heliyon 10:2, pages e24559.
Crossref
Marianna Sirico, Alberto D’Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni & Ugo De Giorgi. (2023) Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers 15:3, pages 703.
Crossref
Qingfang Li, Zhihui Li, Ting Luo & Huashan Shi. (2022) Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Molecular Biomedicine 3:1.
Crossref
Mariana Tannoury, Delphine Garnier, Santos A. Susin & Brigitte Bauvois. (2022) Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?. Cancers 14:24, pages 6026.
Crossref
Hye-Young Min & Ho-Young Lee. (2022) Molecular targeted therapy for anticancer treatment. Experimental & Molecular Medicine 54:10, pages 1670-1694.
Crossref
Kamira Maharaj, Angimar Uriepero, Eva Sahakian & Javier Pinilla-Ibarz. (2022) Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Frontiers in Immunology 13.
Crossref
Adrian Minson, Constantine Tam, Michael Dickinson & John F. Seymour. (2022) Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. Cancers 14:5, pages 1276.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.